200,000+ products from a single source!

sales@angenechem.com

Home > Pyridines > 115900-75-9

115900-75-9

115900-75-9 | 4(1H)-Pyridinone, 1,2-diethyl-3-hydroxy-

CAS No: 115900-75-9 Catalog No: AG000H2X MDL No:MFCD00869703

Product Description

Catalog Number:
AG000H2X
Chemical Name:
4(1H)-Pyridinone, 1,2-diethyl-3-hydroxy-
CAS Number:
115900-75-9
Molecular Formula:
C9H13NO2
Molecular Weight:
167.2050
MDL Number:
MFCD00869703
IUPAC Name:
1,2-diethyl-3-hydroxypyridin-4-one
InChI:
InChI=1S/C9H13NO2/c1-3-7-9(12)8(11)5-6-10(7)4-2/h5-6,12H,3-4H2,1-2H3
InChI Key:
XIYFEESCIBNMIC-UHFFFAOYSA-N
SMILES:
CCc1c(O)c(=O)ccn1CC
UNII:
G3PX21X7IU

Properties

Complexity:
253  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
167.095g/mol
Formal Charge:
0
Heavy Atom Count:
12  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
167.208g/mol
Monoisotopic Mass:
167.095g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
40.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.3  

Literature

Title Journal
Identifying chelators for metalloprotein inhibitors using a fragment-based approach. Journal of medicinal chemistry 20110127
Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94. Biochimica et biophysica acta 20110101
An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection. Photochemistry and photobiology 20110101
The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochemistry and photobiology 20100101
Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology (Basel, Switzerland) 20090101
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. Journal of cancer research and clinical oncology 20080801
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. The British journal of dermatology 20080801
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents. European journal of medicinal chemistry 20080501
Topical applications of iron chelators in photosensitization. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 20071201
Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochemistry and photobiology 20070101
Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20070101
Spectroscopic and potentiometric characterization of oxovanadium(IV) complexes formed by 3-hydroxy-4-pyridinones. Rationalization of the influence of basicity and electronic structure of the ligand on the properties of V(IV)O species in aqueous solution. Inorganic chemistry 20061002
Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers in surgery and medicine 20060401
Characterization of two isomeric beta-d-glucosiduronic acids derived from 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rat liver homogenate incubates. The Journal of pharmacy and pharmacology 20020701
Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrobial agents and chemotherapy 19940501

© 2019 Angene International Limited. All rights Reserved.